[to top of second column]
"In general, we need new technologies, such as the insect cell approach, that do not require egg-based growth of the vaccine, which is slow and has problems," said Mullican, the Emory researcher.
Dr. Andrew Pekosz at Johns Hopkins University's Bloomberg School of Public Health said the speedier technique could save lives. "The most important thing about these new technologies is the speed in which a vaccine can be generated," he said.
Pekosz said the insect cell method of making vaccines doesn't make it more dangerous. "The vaccine itself is purified away from the components of the insect cell," he said.
While awaiting successful clinical trials, Mexican officials are moving forward, trying to buy what vaccine they can.
Cordova said Thursday that Sanofi Pasteur, a division of Sanofi-Aventis, has guaranteed to send 1 million doses by the end of November. Cordova said the doses will be used to vaccinate health care workers.
The company will provide 4 million more doses by the end of December and 15 million by the end of January, Cordova said. Sanofi Pasteur officials reached the agreement with Mexico's president in a meeting Thursday morning.
Ten million additional doses will be manufactured by London-based GlaxoSmithKline, Cordova said.
A new wave of swine flu began to flare up in Mexico last month, and officials say it will continue into early 2010. As of Monday, Mexico has had 45,809 reported cases of swine flu and 271 deaths.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Recent articles
Back to top
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Law & Courts |
Spiritual Life |
Health & Fitness |
Calendar | Letters to the Editor